VINCENT TAM to Prospective Studies
This is a "connection" page, showing publications VINCENT TAM has written about Prospective Studies.
Connection Strength
0.360
-
Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
Score: 0.069
-
Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11).
Score: 0.068
-
Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
Score: 0.064
-
Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.
Score: 0.054
-
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.
Score: 0.025
-
Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
Score: 0.024
-
Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.
Score: 0.015
-
Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30.
Score: 0.015
-
A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
Score: 0.011
-
Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
Score: 0.008
-
Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4.
Score: 0.006